---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-028345"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:25:37.013027+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics reports Q4 2024 net loss of $37.7M; cash runway into 3Q 2026

## Summary
- Net loss of $37.7M for Q4 2024 ($0.35 per share) vs $30.8M loss in Q4 2023; full year net loss $130.3M ($1.19 per share).
- Cash and marketable securities $257.9M as of Dec 31, 2024; expected to fund operations into 3Q 2026.
- TNG462 granted FDA Orphan Drug Designation for pancreatic cancer; Phase 1/2 data update expected in 2025.
- IND for TNG456 cleared; Phase 1/2 enrollment expected 1H 2025; clinical collaboration with Lilly for abemaciclib combination.
- TNG260 proof-of-mechanism established; dose expansion ongoing in lung cancer; clinical update expected 2025.

## SEC filing metadata
- accession: 0000950170-25-028345
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000095017025028345/0000950170-25-028345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000095017025028345/tngx-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-028345
- JSON: https://secwatch.observer/filing/0000950170-25-028345.json
- Plain text: https://secwatch.observer/filing/0000950170-25-028345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.